Summary:
In patients with early diabetic kidney disease (DKD), calcitriol supplementation significantly reduced renal inflammation and tubular injury compared to placebo or standard care,
though it was associated with no major adverse effects reported, but further studies are needed to confirm safety and optimal dosing.
| PICO | Description |
|---|---|
| Population | Patients diagnosed with early diabetic kidney disease (early DKD), characterized by mild to moderate renal impairment and evidence of renal inflammation and tubular injury. |
| Intervention | Administration of calcitriol (active vitamin D analog) at doses and duration as specified in the randomized controlled trial to modulate renal inflammation and tubular injury. |
| Comparison | Placebo or standard care without calcitriol supplementation, serving as the control group in the randomized controlled trial. |
| Outcome | Calcitriol significantly reduced markers of renal inflammation and tubular injury, with potential benefits on podocyte injury. The intervention suggested renoprotection in early DKD patients. No significant adverse events were reported; however, further investigation into optimal dosing and long-term safety is warranted. |
Source: Pringgodigdo Nugroho, et al. “Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial.” Read article here.
